VIR Jan 2025 7.500 put
| Previous Close | 1.1600 |
| Open | 0.5000 |
| Bid | 0.8000 |
| Ask | 0.9500 |
| Strike | 7.50 |
| Expire Date | 2025-01-17 |
| Day's Range | 0.5000 - 1.1600 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 13 |
Business WireVir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
SAN FRANCISCO, October 03, 2024--Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that Mark Eisner, M.D., M.P.H., Executive Vice President and Chief Medical Officer, is scheduled to participate in a fireside chat at the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference on Tuesday, October 8, at 10:00 a.m. PT / 1:00 p.m. ET.
Business WireVir Biotechnology Appoints Jason O’Byrne as Chief Financial Officer
SAN FRANCISCO, September 10, 2024--Vir Biotechnology Inc. (Nasdaq: VIR) today announced that Jason O’Byrne, MBA, is appointed as Executive Vice President and Chief Financial Officer (CFO), effective October 2, 2024. Mr. O’Byrne will join the Vir Executive Management Team and report directly to the company’s Chief Executive Officer, Marianne De Backer, M.Sc., Ph.D., MBA.
Business WireVir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers
SAN FRANCISCO, September 09, 2024--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the exclusive worldwide license agreement with Sanofi announced on August 1, 2024, has closed following expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The agreement provides Vir with an exclusive worldwide license to three clinical-stage masked T-cell engagers (TCEs) with potential applications in a range of cancers and exclusive use of the proprietary P
